<DOC>
	<DOCNO>NCT02537028</DOCNO>
	<brief_summary>The primary purpose Phase 1b double-blind , randomize , placebo-controlled trial evaluate safety , tolerability , pharmacokinetic ( PK ) , biological effect MSC2364447C administer 4 week systemic lupus erythematosus subject ( SLE ) .</brief_summary>
	<brief_title>MSC2364447C Phase 1b Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Male female 18 65 year age Diagnosis systemic lupus erythematosus ( SLE ) ( least 4 11 American College Rheumatology [ ACR ] classification criterion SLE ) least 6 month duration Screening visit Positive test result antinuclear antibody ( ANA ) ( human epithelial cell2 ANA great equal [ &gt; = ] 1:80 ) and/or antidsDNA antibody ( &gt; = 30 international unit per milliliter [ IU/mL ] ) Screening visit At least 1 SLE disease manifestation ( assessed Systemic Lupus Erythematosus Disease Activity Index2000 [ SLEDAI2K ] ) positive antidsDNA central nervous system ( CNS ) SLE ( psychosis , organic brain syndrome , cranial nerve disorder , lupus headache , newonset cerebrovascular accident ) History vaccination follow vaccination pathogen Screening : 1 . Vaccination Streptococcus pneumoniae pneumococcal polysaccharide vaccine 23 pneumococcal 13valent conjugate vaccine per local guideline , 2 . Vaccination influenza virus ( per local seasonal recommendation ) . Subjects receive 1 vaccination screen must least 2 week vaccination ( ) date randomization Day 1 . Other protocol define inclusion criterion could apply Active clinically significant CNS SLE Initiation change dose antimalarial treatment screen visit Within 2 week prior Screening Screening : use oral corticosteroid great ( &gt; ) 40 mg daily prednisone equivalent , use injectable corticosteroid , change dose corticosteroid Within 2 week prior Screening , initiation change dose angiotensinconverting enzyme inhibitor angiotensin receptor blocker , nonsteroidal antiinflammatory drug ( NSAIDs ) . Within 2 month prior Screening Screening : initiation change dose methotrexate , mycophenolate ( mofetil sodium ) , azathioprine Within 2 month prior Screening Screening , use cyclosporine , tacrolimus , leflunomide , abatacept , antitumor necrosis factor alpha agent , intravenous immunoglobulin , plasmapheresis , diseasemodifying , immunosuppressive , immunomodulatory therapy otherwise specify protocol Within 6 month prior Screening Screening : use cyclophosphamide chlorambucil Within 12 month prior screen screening : use rituximab , belimumab , B celldepleting modulate therapy Within 1 month prior Screening Screening , vaccination live liveattenuated virus vaccine . Active clinically significant viral , bacterial fungal infection , serious episode infection require hospitalization within last 6 month Estimated glomerular filtration rate Modification Diet Renal Disease equation le ( &lt; ) 60 milliliter per minute per 1.73 square meter ( mL/min/1.73 m^2 ) , recent decline kidney function , proteinuria &gt; = 3 gram per day ( g/day ) ( spot urine protein/creatinine ratio &gt; = 3 mg/mg ) Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MSC2364447C</keyword>
	<keyword>Phase 1</keyword>
	<keyword>BTK inhibitor</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>M2951</keyword>
	<keyword>Lupus</keyword>
</DOC>